Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Company Overview - Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD) and aims to transform CAD into a screenable, diagnosable, and manageable condition [4] - The company offers Heartflow One, a complete, non-invasive, precision coronary care platform that provides patient insights throughout the guideline-directed CCTA pathway [4] - Heartflow's AI-driven platform includes Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis, supported by the ACC/AHA Chest Pain Guideline and backed by over 600 peer-reviewed publications [4] - The company has assisted clinicians in managing over 400,000 patients globally [4] IPO Details - Heartflow announced the closing of its upsized initial public offering (IPO) of 19,166,667 shares at a public offering price of $19 per share, resulting in total gross proceeds of approximately $364.2 million before deductions [1] - The offering included 2,500,000 shares issued upon the full exercise of the underwriters' option to purchase additional shares [1] - Heartflow's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "HTFL" on August 8, 2025 [1] - J.P. Morgan, Morgan Stanley, and Piper Sandler acted as joint book-running managers for the offering, with Stifel and Canaccord Genuity serving as co-managers [1]